Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of 4.00
Press release Maxim Group initiates the coverage of the CROSSJECT share with…
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest…